Medications development for opioid abuse

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 1, 2013, Pages

  Stevens Negus, S ^a   Banks, Matthew L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878990727     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012104     Document Type: Article

References (56)

1. Ahn K., McKinney MK, Cravatt BF. 2008. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707.
2. Ator N.A., Griffiths RR. 2003. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70: S55-S72.
3. Caine S.B., Negus SS, Mello NK. 1999. Method for training operant responding and evaluating cocaine self-administration behavior in mutant mice. Psychopharmacology 147: 22-24.
4. Comer S.D., Collins ED, Fischman MW. 2001. Buprenorphine sublingual tablets: Effects on IV heroin self-administration by humans. Psychopharmacology 154: 28-37.
5. Comer S.D., Walker EA, Collins ED. 2005. Buprenorphine/ naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 181: 1-12.
6. Comer S.D., Sullivan MA, Hulse GK. 2007. Sustained-release naltrexone: Novel treatment for opioid dependence. Expert Opin Investig Drugs 16: 1285-1294.
7. Del Arco I, Navarro M, Bilbao A, Ferrer B, Piomelli D, Rodriguez De Fonseca F. 2002. Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor am404. Eur J Pharmacol 454: 103-104.
8. Gerber G.J., Bozarth MA, Spindler JE, Wise RA. 1985. Concurrent heroin self-administration and intracranial selfstimulation in rats. Pharmacol Biochem Behav 23: 837-842.
9. Gold M.S., Redmond DEJr, Kleber HD. 1979. Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. Am J Psychiatry 136: 100-102.
10. Gonzalez G., Oliveto A, Kosten TR. 2004. Combating opiate dependence: A comparison among the available pharmacological options. Expert Opin Pharmacother 5: 713-725.
11. Greenwald M.K., Hursh SR. 2006. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply. Drug Alcohol Depend 85: 35-48.
12. Greenwald M.K., Steinmiller CL. 2009. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of alternative reinforcer magnitude and post-session drug supply. Drug Alcohol Depend 104: 84-93.
13. Greenwald M., Schuh K, Hopper J, Schuster C, Johanson CE. 2002. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160: 344-352.
14. Griffiths R.R., Wurster RM, Brady JV. 1975. Discrete-trial choice procedure: Effects of naloxone and methadone on choice between food and heroin. Pharmacol Rev 27: 357-365.
15. Griffiths R.R., Wurster RM, Brady JV. 1981. Choice between food and heroin: Effects of morphine, naloxone, and secobarbital. J Exp Anal Behav 35: 335-351.
16. Haney M., Spealman R. 2008. Controversies in translational research: Drug self-administration. Psychopharmacology 199: 403-419.
17. He S., Li N, Grasing K. 2004. Long-term opiate effects on amphetamine-induced dopamine release in the nucleus accumbens core and conditioned place preference. Pharmacol Biochem Behav 77: 327-335.
18. Heyman GM. 2009. Addiction: A disorder of choice. Harvard University Press, Cambridge, MA.
19. Hutchinson M.R., Bland ST, JohnsonKW, Rice KC, Maier SF, Watkins LR. 2007. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J Sci 7: 98-111.
20. Hutchinson M.R., Lewis SS, Coats BD, Skyba DA, Crysdale NY, Berkelhammer DL, Brzeski A, Northcutt A, Vietz CM, Judd CM, et al. 2009. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic av411 (ibudilast). Brain Behav Immun 23: 240-250.
21. Hutchinson M.R., Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, et al. 2010. Evidence that opioids may have toll-like receptor 4 and md-2 effects. Brain Behav Immun 24: 83-95.
22. Jasinski D.R., Johnson RE, Kocher TR. 1985. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42: 1063-1066.
23. Johanson C.E., Balster RL. 1978. A summary of the results of a drug self-administration study using substitution procedures in rhesus monkeys. Bull Narc 30: 43-54.
24. Katz JL. 1989. Drugs as reinforcers: Pharmacological and behavioural factors. In The neuropharmacological basis of reward (ed. Liebman JM, Cooper SJ), pp. 164-213. Clarendon, Oxford.
25. Liu L., Coller JK, Watkins LR, Somogyi AA, Hutchinson MR. 2011. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain Behav Immun25: 1223-1232.
26. Logrip M.L., Koob GF, Zorrilla EP. 2011. Role of corticotropin-releasing factor in drug addiction: Potential for pharmacological intervention. CNS Drugs 25: 271-287.
27. Manchikanti L., Singh A. 2008. Therapeutic opioids: A tenyear perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Phys 11: S63-S88.
28. Manwell L.A., Satvat E, Lang ST, Allen CP, Leri F, Parker LA. 2009. Faah inhibitor, URB-597, promotes extinction and CB1 antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94: 154-162.
29. Mello N.K., Negus SS. 1996. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424.
30. Mello N.K., Mendelson JH, Kuehnle JC. 1982. Buprenorphine effects on human heroin self-administration: An operant analysis. J Pharmacol Exp Ther 223: 30-39.
31. Mika J., Wawrzczak-Bargiela A, Osikowicz M, Makuch W, Przewlocka B. 2009. Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun 23: 75-84.
32. Negus SS. 2006. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: Effects of naloxone, buprenorphine, and methadone. J Pharmacol Exp Ther 317: 711-723.
33. Negus SS. 2009. Opioid antagonist effects in animal models related to opioid abuse: Drug discrimination and drug self-administration. In Opioid receptors and antagonists: From bench to clinic (ed. Dean EJ, Bilsky R, Negus SS), pp. 221-226. Humana, New York.
34. Negus S.S., Banks ML. 2011. Making the right choice: Lessons from drug discrimination for research on drug reinforcement and drug self-administration. In Drug discrimination: Applications to medicinal chemistry and drug studies (ed. Glennon R, Young R), pp. 361-388. Wiley, Hoboken, NJ.
35. Negus S.S., Rice KC. 2009. Mechanisms of withdrawal-associated increases in heroin self-administration: Pharmacologic modulation of heroin vs food choice in heroindependent rhesus monkeys. Neuropsychopharmacology 34: 899-911.
36. Negus S.S., Woods JH. 1995. Reinforcing effects, discriminative stimulus effects, and physical dependence liability of buprenorphine. In Buprenorphine:Combatting drug abuse with a unique opioid (ed. Cowan A, Lewis JW), pp. 71-101. Wiley-Liss, New York.
37. O'Connor EC, Chapman K, Butler P, Mead AN. 2011. The predictive validity of the rat self-administration model for abuse liability. Neurosci Biobehav Rev 35: 912-938.
38. Raghavendra V., Tanga FY, DeLeo JA. 2003. Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29: 327-334.
39. Ramesh D., Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt B.F., et al. 2011. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173-185.
40. SAMHSA (Substance Abuse and Mental Health Services Administration). 2011. Results from the 2010 national survey on drug use and health. Rockville, MD.
41. Sell S.L., France CP. 2002. Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. J Pharmacol Exp Ther 301: 1103-1110.
42. Sevarino K., Kosten T. 2007. Naltrexone for initiation and maintenance of opiate abstinence. In Opioid receptors and antagonists: From bench to clinic (ed. Dean R, Bilsky EJ, Negus SS). Humana, New York.
43. Shahidi S., Hasanein P. 2011. Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms. Brain Res Bull 86: 118-122.
44. Song P., Zhao Z-Q. 2001. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39: 281-286.
45. Spragg SDS. 1940. Morphine addiction in chimpanzees. Comp Psychol Mono 15: 5-132.
46. Sullivan M., Vosburg S, Comer S. 2006. Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189: 37-46.
47. Tawfik V.L., LaCroix-Fralish ML, Nutile-McMenemy N, DeLeo JA. 2005. Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J Pharmacol Exp Ther 313: 1239-1247.
48. Thompson T., Schuster CR. 1964. Morphine self-administration, food-reinforced, and avoidance behaviors in rhesus monkeys. Psychopharmacologia 5: 87-94.
49. Vela G., Ruiz-gayo M, Fuentes JA. 1995. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34: 665-668.
50. Viganò D, Valenti M, Grazia Cascio M, DiMarzo V, Parolaro D, Rubino T. 2004. Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci 20: 1849-1857.
51. Watkins L.R., Hutchinson MR, Rice KC, Maier SF. 2009. The "toll" of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30: 581-591.
52. Wee S., Koob GF. 2010. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 210: 121-135.
53. Wurster R.M., Griffiths RR, Findley JD, Brady JV. 1977. Reduction of heroin self-administration in baboons by manipulation of behavioral and pharmacological conditions. Pharmacol Biochem Behav 7: 519-528.
54. Yamaguchi T., Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y., Watanabe S, Yamamoto T. 2001. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 909: 121-126.
55. Yanagita T. 1978. Drug dependence studies in laboratory animals. NIDA Res Monogr 19: 179-190.
56. Young A.M., Herling S. 1986. Drugs as reinforcers: Studies in laboratory animals. In Behavioral analysis of drug dependence (ed. Goldberg SR, Stolerman IP), pp. 9-67. Academic, Orlando, FL.